Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	2 shs
GMAB Genmab A/S	$19.96 -1.2%	$21.28	$18.64 ▼ $31.88	$13.21B	0.98	899,063 shs	1.37 million shs
TEVA Teva Pharmaceutical Industries	$16.50 +0.1%	$18.47	$12.51 ▼ $22.80	$18.70B	0.82	13.00 million shs	12.13 million shs
UTHR United Therapeutics	$305.39 -0.6%	$351.85	$221.53 ▼ $417.82	$13.72B	0.64	446,120 shs	443,446 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	+78.24%
GMAB Genmab A/S	-0.25%	-16.14%	+8.13%	-2.13%	-35.70%
TEVA Teva Pharmaceutical Industries	+2.42%	+3.90%	-1.72%	-1.67%	+22.59%
UTHR United Therapeutics	+0.88%	-1.25%	-11.15%	-15.08%	+24.39%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	3.9913 of 5 stars	4.4	3.0	0.0	0.0	2.4	0.0	3.1
TEVA Teva Pharmaceutical Industries	2.8988 of 5 stars	3.4	3.0	0.8	0.0	2.9	1.7	0.6
UTHR United Therapeutics	4.7663 of 5 stars	3.3	1.0	0.0	4.6	3.6	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	2.20	Hold	$58.43	-10.07% Downside
GMAB Genmab A/S	2.77	Moderate Buy	$41.33	107.08% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	42.03% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$388.25	27.13% Upside

Current Analyst Ratings Breakdown

Latest ALPN, TEVA, GMAB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
3/11/2025	GMAB Genmab A/S	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
2/27/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
2/13/2025	GMAB Genmab A/S	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/13/2025	GMAB Genmab A/S	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$27.00
2/11/2025	GMAB Genmab A/S	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
1/30/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
1/30/2025	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $26.00
1/23/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
1/23/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $30.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
GMAB Genmab A/S	$21.53B	0.61	$1.35 per share	14.80	$8.04 per share	2.48
TEVA Teva Pharmaceutical Industries	$16.54B	1.13	$3.27 per share	5.05	$4.75 per share	3.47
UTHR United Therapeutics	$2.88B	4.77	$18.36 per share	16.63	$127.35 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
GMAB Genmab A/S	$1.14B	$1.74	11.47	11.21	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	6.27	1.44	-9.91%	42.46%	6.65%	5/14/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.41	11.11	0.97	40.31%	19.22%	16.15%	5/7/2025 (Estimated)

Latest ALPN, TEVA, GMAB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 24	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.13%	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
GMAB Genmab A/S	N/A	5.25	5.24
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
GMAB Genmab A/S	7.07%
TEVA Teva Pharmaceutical Industries	54.05%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
GMAB Genmab A/S	1.54%
TEVA Teva Pharmaceutical Industries	0.55%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	Optionable
GMAB Genmab A/S	2,204	661.77 million	651.58 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.13 billion	1.13 billion	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

ALPN, TEVA, GMAB, and UTHR Headlines

Recent News About These Companies

Zurcher Kantonalbank Zurich Cantonalbank Has $11.46 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

March 13 at 4:06 AM | marketbeat.com

Amundi Has $42.97 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

March 13 at 3:56 AM | marketbeat.com

Wealthfront Advisers LLC Acquires 18,313,424 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 12 at 6:56 AM | marketbeat.com

Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update

March 11 at 11:10 PM | seekingalpha.com

United Therapeutics Co. (NASDAQ:UTHR) Stake Raised by AlphaQuest LLC

March 11 at 4:38 AM | marketbeat.com

918 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Callan Family Office LLC

March 11 at 4:02 AM | marketbeat.com

Ruffer LLP Invests $4.04 Million in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 7:55 AM | marketbeat.com

Edgestream Partners L.P. Boosts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 4:33 AM | marketbeat.com

Ashton Thomas Private Wealth LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

March 10 at 4:33 AM | marketbeat.com

Andra AP fonden Purchases 5,500 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 8, 2025 | marketbeat.com

Candriam S.C.A. Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

March 7, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Victory Capital Management Inc.

March 7, 2025 | marketbeat.com

Seizert Capital Partners LLC Acquires 1,312 Shares of United Therapeutics Co. (NASDAQ:UTHR)

March 5, 2025 | marketbeat.com

Assetmark Inc. Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

March 5, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lifted by Fisher Asset Management LLC

March 5, 2025 | marketbeat.com

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

March 4, 2025 | finance.yahoo.com

Westover Capital Advisors LLC Invests $679,000 in United Therapeutics Co. (NASDAQ:UTHR)

March 4, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Oppenheimer & Co. Inc.

March 4, 2025 | marketbeat.com

Leerink Partnrs Issues Pessimistic Outlook for UTHR Earnings

March 4, 2025 | americanbankingnews.com

LGT Fund Management Co Ltd. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

March 3, 2025 | marketbeat.com

Q2 EPS Estimate for United Therapeutics Lowered by Analyst

March 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, TEVA, GMAB, and UTHR Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Genmab A/S NASDAQ:GMAB

$19.96 -0.25 (-1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$19.96 +0.00 (+0.03%)

As of 04:05 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Teva Pharmaceutical Industries NYSE:TEVA

$16.50 +0.02 (+0.09%)

Closing price 03:59 PM Eastern

Extended Trading

$16.52 +0.03 (+0.18%)

As of 04:26 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

United Therapeutics NASDAQ:UTHR

$305.39 -1.70 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$305.88 +0.49 (+0.16%)

As of 04:25 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time